This article provides a comprehensive, data-driven comparison of five highly anticipated US biotech IPOs projected for 2026. We delve into their therapeutic areas, clinical pipelines, market opportunities, and potential risks, offering valuable insights for investors eyeing the next big wave in biopharmaceutical innovation.